[Drugs in development for the treatment of osteoporosis:Raloxifene].
Taga
Michiyoshi
M
Department of OB/GYN, Teikyo University, Mizonokuchi Hospital.
D015519:Bone Density; D016723:Bone Remodeling; D004965:Estrogen Antagonists; D005260:Female; D015775:Fractures, Stress / Q000517:prevention & control; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use; D016103:Spinal Fractures / Q000517:prevention & control
D004965:Estrogen Antagonists; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride